Podcast | Practice of Medicine | April 25, 2022
A Discussion About the Safety of Recombinant Zoster Vaccine in Rheumatology Patients
Herpes zoster is a public health concern for the public, especially in subjects who are immunocompromised. The CDC–recommended recombinant zoster vaccine (RZV) is an effective way to reduce the incidence of herpes zoster, but because of the increased immunogenicity of the vaccine adjuvant, there is a concern about flares of underlying autoimmune diseases in rheumatology patients.